IMPAIRMENT, RESTRUCTURING AND OTHER

3 Months Ended

Jan. 01, 2022

Restructuring and Related Activities [Abstract]

Activity described herein is classified within the “Cost of sales—impairment, restructuring and other” and “Impairment, restructuring and other” lines in the Condensed Consolidated Statements of Operations. The following table details impairment, restructuring and other charges for each of the periods presented:


	Three Months Ended
		January 1, 2022		January 2, 2021

Cost of sales—impairment, restructuring and other:
COVID-19 related costs		$	—	$	8.7
Restructuring and other charges, net		—		0.3

Operating expenses:
COVID-19 related costs		—		0.6
Restructuring and other charges, net		1.8		0.1

Impairment, restructuring and other charges from continuing operations		$	1.8	$	9.7

The following table summarizes the activity related to liabilities associated with restructuring and other during the three months ended January 1, 2022:


Amounts accrued for restructuring and other at September 30, 2021	$	1.9


Payments and other	(0.2)
Amounts accrued for restructuring and other at January 1, 2022	$	1.7

Included in restructuring accruals, as of January 1, 2022, is $0.6 that is classified as long-term. Payments against the long-term accruals will be incurred as the employees covered by the restructuring plan retire or through the passage of time. The remaining amounts accrued will continue to be paid out over the course of the next twelve months.

COVID-19

The COVID-19 pandemic has had, and continues to have, an impact on financial markets, economic conditions, and portions of the Company’s business and industry. The Company has actively addressed the pandemic’s ongoing impact on its employees, operations, customers, consumers, and communities, by, among other things, implementing contingency plans, making operational adjustments where necessary, and providing assistance to organizations that support front-line workers. Many of the Company’s employees continue to work from home. In those instances where the Company’s employees cannot perform their work at home, the Company has implemented additional health and safety measures and social distancing protocols, consistent with government recommendations and/or requirements, to help to ensure their safety. In addition, the Company implemented an interim premium pay allowance for certain associates in its field sales force and its manufacturing or distribution centers during fiscal 2020 and 2021. Costs incurred during the three months ended January 1, 2022 related to COVID-19 were immaterial. During the three months ended January 2, 2021, the Company incurred costs of $9.3 associated with the COVID-19 pandemic primarily related to premium pay. The Company incurred costs of $8.3 in its U.S. Consumer segment and $0.4 in its Hawthorne segment in the “Cost of sales—impairment, restructuring and other” line in the Condensed Consolidated Statements of Operations during the three months ended January 2, 2021. The Company incurred costs of $0.6 in its U.S. Consumer segment in the “Impairment, restructuring and other” line in the Condensed Consolidated Statements of Operations during the three months ended January 2, 2021.